Identification of TRIB1 R107L gain-of-function mutation in human acute megakaryocytic leukemia

31Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Trib1 has been identified as a myeloid oncogene in a murine leukemia model. Here we identified a TRIB1 somatic mutation in a human case of Down syndrome-related acute megakaryocytic leukemia. The mutation was observed at well-conserved arginine 107 residue in the pseudokinase domain. This R107L mutation remained in leukocytes of the remission stage in which GATA1 mutation disappeared, suggesting the TRIB1 mutation is an earlier genetic event in leukemogenesis. The bone marrow transfer experiment showed that acute myeloid leukemia development was accelerated by transducing murine bone marrow cells with the R107L mutant in which enhancement of ERK phosphorylation and C/EBPα degradation by Trib1 expression was even greater than in those expressing wild-type. These results suggest that TRIB1 may be a novel important oncogene for Down syndrome-related acute megakaryocytic leukemia. © 2012 by The American Society of Hematology.

Cite

CITATION STYLE

APA

Yokoyama, T., Toki, T., Aoki, Y., Kanezaki, R., Park, M. J., Kanno, Y., … Nakamura, T. (2012). Identification of TRIB1 R107L gain-of-function mutation in human acute megakaryocytic leukemia. Blood, 119(11), 2608–2611. https://doi.org/10.1182/blood-2010-12-324806

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free